Evolution of the Average Target: XP Inc.

Evolution of the Target Price: XP Inc.

Changes in Analyst Recommendations: XP Inc.

8.IGOs5TNPt0fW-u_9SUuvFuAP-cHvxa393228SHkggj0.czT51EB--CW1sK3JJSLeZaVKtbOOpvWTqTfYCxhptkl1GcCiAnbtcfuiiA~036b275c249f146743a031088d3a5100
31/08 Itau BBA Upgrades XP to Outperform From Market Perform, Adjusts PT to $22 From $19 MT
02/04 UBS Adjusts Price Target on XP to $28 From $25, Maintains Buy Rating MT
20/01 Jefferies Initiates XP at Buy With $22 Price Target MT
16/12 UBS Adjusts XP Price Target to $25 From $23, Maintains Buy Rating MT
16/25/16 UBS Adjusts Price Target on XP to $23 From $24, Maintains Buy Rating MT
24/25/24 XP Shares Drop After Downgrade From Itau BBA MT
23/25/23 Itau BBA Downgrades XP to Market Perform From Outperform, Adjusts Price Target to $21 From $20 MT
10/25/10 UBS Adjusts XP Price Target to $24 From $17, Maintains Buy Rating MT
04/25/04 Goldman Sachs Upgrades XP to Buy From Neutral, $23 Price Target MT
13/25/13 XP Shares Rise After Morgan Stanley Upgrades to Overweight From Equalweight MT
13/25/13 Morgan Stanley Upgrades XP to Overweight From Equalweight, Adjusts Price Target to $24 From $18 MT
07/25/07 UBS Adjusts Price Target on XP to $17 From $16, Keeps Buy Rating MT
18/25/18 Itau BBA Initiates XP at Outperform With $20 Price Target MT
25/25/25 XP Shares Rise After Upgrade From UBS MT
24/25/24 UBS Upgrades XP to Buy From Neutral, Cuts Price Target to $16 From $19 MT
10/24/10 BofA Securities Downgrades XP to Neutral From Buy, Price Target is $16 MT
25/24/25 UBS Cuts Price Target on XP to $19 From $21, Maintains Neutral Rating MT
11/24/11 UBS Downgrades XP to Neutral From Buy, Cuts Price Target to $21 From $30 MT
05/24/05 Bradesco BBI Downgrades XP to Neutral From Outperform, Cuts Price Target to $19 From $31 MT
05/24/05 Citigroup Adjusts Price Target on XP to $27 From $29, Maintains Buy Rating MT
01/24/01 XP Shares Decline After Goldman Sachs Downgrade MT
30/24/30 Goldman Sachs Downgrades XP to Neutral From Buy, Cuts Price Target to $23 From $30 MT
23/24/23 Morgan Stanley Downgrades XP to Equalweight From Overweight, Adjusts Price Target to $24 From $31 MT
22/24/22 Citigroup Adjusts Price Target on XP to $29 From $28, Maintains Buy Rating MT
11/23/11 UBS Adjusts XP Price Target to $30 From $31, Maintains Buy Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+42.57%
+41.03%
+18.65%
+39.07%
+36.75%
+15.06%
- +1.46%
Average +27.80%
Weighted average by Cap. +32.58%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
102.07BRL
Average target price
119.04BRL
Spread / Average Target
+16.62%
High Price Target
134.16BRL
Spread / Highest target
+31.44%
Low Price Target
103.67BRL
Spread / Lowest Target
+1.56%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
Global
Quality
ESG MSCI
-